Metabolic dysfunction in diabetic cardiomyopathy.
Metabolic dysfunction in diabetic cardiomyopathy.
复制标题
DOI：
10.1007/s10741-013-9377-8
复制
发表时间：
2014-01
影响因子：
4.6
通讯作者：
Wold, Loren E.
中科院分区：
文献类型：
--
作者：
Isfort, Michael;Stevens, Sarah C. W.;Schaffer, Stephen;Jong, Chian Ju;Wold, Loren E.
糖尿病性心肌病（DCM）被定义为糖尿病期间独立于血管并发症的心脏疾病。在全世界，DCM的新病例数与新诊断的糖尿病（DM）病例成比例地以流行病的速度上升。DCM是一种在糖尿病患者中发现的心衰综合征，其特征是左心室肥厚和舒张功能降低，伴有或不伴有收缩功能障碍，发生在没有高血压和冠状动脉疾病的情况下。DCM和其他糖尿病并发症的部分原因是血糖和血脂升高，这是糖尿病的特征。尽管高血糖和高脂血症有病理后果，但这两种代谢异常的结合加剧了糖尿病并发症的严重程度。心脏中葡萄糖和脂肪酸代谢之间存在着一种自然竞争，这种竞争受到变构和反馈控制以及关键限制酶的转录调节的调节。抑制这些糖酵解酶不仅可以控制糖酵解途径中底物的通量，还可以导致糖酵解中间底物通过病理途径转移，从而介导糖尿病并发症的发生。目前的审查描述了这些病理途径的发展所涉及的限制步骤和这些限制步骤的调节所涉及的因素。此外，还描述了对DCM具有证明或假设作用的治疗方案。
Diabetic cardiomyopathy (DCM) is defined as cardiac disease independent of vascular complications during diabetes. The number of new cases of DCM is rising at epidemic rates in proportion to newly diagnosed cases of diabetes mellitus (DM) throughout the world. DCM is a heart failure syndrome found in diabetic patients that is characterized by left ventricular hypertrophy and reduced diastolic function, with or without concurrent systolic dysfunction, occurring in the absence of hypertension and coronary artery disease. DCM and other diabetic complications are caused in part by elevations in blood glucose and lipids, characteristic of DM. Although there are pathological consequences to hyperglycemia and hyperlipidemia, the combination of the two metabolic abnormalities potentiates the severity of diabetic complications. A natural competition exists between glucose and fatty acid metabolism in the heart that is regulated by allosteric and feedback control and transcriptional modulation of key limiting enzymes. Inhibition of these glycolytic enzymes not only controls flux of substrate through the glycolytic pathway, but also leads to the diversion of glycolytic intermediate substrate through pathological pathways, which mediate the onset of diabetic complications. The present review describes the limiting steps involved in the development of these pathological pathways and the factors involved in the regulation of these limiting steps. Additionally, therapeutic options with demonstrated or postulated effects on DCM are described.
登录
查看更多内容
影响因子：
7.7
作者：
AFZAL, N;GANGULY, PK;DHALLA, NS
通讯作者：
DHALLA, NS
DOI：
10.1152/ajpendo.00573.2003
发表时间：
2004-10-01
影响因子：
5.1
作者：
Chabowski, A;Coort, SLM;Bonen, A
通讯作者：
Bonen, A
影响因子：
2.7
作者：
COTTER, MA;CAMERON, NE;ROBERTSON, S
通讯作者：
ROBERTSON, S
DOI：
10.1152/ajpendo.00358.2003
发表时间：
2004-05-01
影响因子：
5.1
作者：
Davidoff, AJ;Mason, MM;Ren, J
通讯作者：
Ren, J
影响因子：
15.9
作者：
Burkart, Eileen M.;Sambandam, Nandakurnar;Kelly, Daniel P.
通讯作者：
Kelly, Daniel P.